Kyverna's Miv-cel Delivers Unprecedented Efficacy in Registrational SPS Trial, Paving Way for BLA Submission
KYTX has more than doubled off its 52-week low of $1.82.
Summary
Kyverna Therapeutics announced highly positive primary analysis results from its registrational trial (KYSA-8) for miv-cel in Stiff Person Syndrome (SPS). The trial demonstrated statistically significant and durable clinical benefits across all primary and secondary endpoints, including a 46% median improvement in the Timed 25-Foot Walk and 81% of patients achieving clinically meaningful improvement. All 26 patients in the trial were able to discontinue chronic immunotherapies. While the company's recent 10-K alluded to positive Phase 2 SPS results and a planned BLA submission, this news provides the detailed primary analysis from the registrational trial, confirming the strong efficacy and offering specific, actionable data. These results are unprecedented for SPS, a debilitating disease with no approved therapies, and position miv-cel as a potential first-in-class treatment. The company is preparing its Biologics License Application (BLA) submission, which is a critical step towards commercialization and could significantly de-risk the program and enhance the company's valuation. Investors will now focus on the timing of the BLA submission and subsequent regulatory review, as well as any further updates on miv-cel's development in other indications like myasthenia gravis.
At the time of this announcement, KYTX was trading at $10.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.9M. The 52-week trading range was $1.82 to $13.67. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.